| Ident. | Authors (with country if any) | Title |
|---|
| 000002 (2021) |
Fabricio Souza Neves [Brésil] | Correlation of the rise and fall in COVID-19 cases with the social isolation index and early outpatient treatment with hydroxychloroquine and chloroquine in the state of Santa Catarina, southern Brazil: A retrospective analysis. |
| 000027 (2021) |
S. Ortonobes Roig [Espagne] ; N. Soler-Blanco ; I. Torrente Jiménez ; E. Van Den Eynde Otero ; M. Moreno-Ari O ; M. G Mez-Valent | [Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients]. |
| 000035 (2021) |
L. Anedda [Italie] ; L. Bianchini ; L. Cuzzolin ; G. Finco ; V. Fanos ; M A Marcialis | What if COVID-19 affects the child: which weapons and how to use them. |
| 000037 (2021) |
Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne] | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. |
| 000046 (2021) |
Paulo Roberto Bignardi [Brésil] ; Carolina Santos Vengrus [Brésil] ; Bruno Matos Aquino [Brésil] ; Alcindo Cerci Neto [Brésil] | Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. |
| 000050 (2021) |
Isabel S. Hernandes [Brésil] ; Haroldo C. Da Silva [Brésil] ; Hélio F. Dos Santos [Brésil] ; Wagner B. De Almeida [Brésil] | Unveiling the Molecular Structure of Antimalarial Drugs Chloroquine and Hydroxychloroquine in Solution through Analysis of 1H NMR Chemical Shifts. |
| 000061 (2021) |
Neils Ben Quashie [Ghana] ; Nancy Odurowah Duah-Quashie [Ghana] | Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. |
| 000068 (2021) |
Cassandra Doyno [États-Unis] ; Diana M. Sobieraj [États-Unis] ; William L. Baker [États-Unis] | Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. |
| 000080 (2021) |
Rong Qiu ; Jingwei Li ; Yuxuan Xiao ; Ziyi Gao ; Yihang Weng ; Qiran Zhang ; Chengdi Wang ; Hanlin Gong [République populaire de Chine] ; Weimin Li | The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. |
| 000118 (2021) |
Carlo Salvarani [Italie] ; Pamela Mancuso [Italie] ; Federica Gradellini [Italie] ; Nilla Viani [Italie] ; Paolo Pandolfi [Italie] ; Massimo Reta [Italie] ; Giuliano Carrozzi [Italie] ; Gilda Sandri [Italie] ; Gianluigi Bajocchi [Italie] ; Elena Galli [Italie] ; Francesco Muratore [Italie] ; Luigi Boiardi [Italie] ; Nicol Pipitone [Italie] ; Giulia Cassone [Italie] ; Stefania Croci [Italie] ; Anna Maria Marata [Italie] ; Massimo Costantini [Italie] ; Paolo Giorgi Rossi [Italie] | Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. |
| 000138 (2021) |
Katharina Habler [Allemagne] ; Mathias Brügel [Allemagne] ; Daniel Teupser [Allemagne] ; Uwe Liebchen [Allemagne] ; Christina Scharf [Allemagne] ; Ulf Schönermarck [Allemagne] ; Michael Vogeser [Allemagne] ; Michael Paal [Allemagne] | Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum. |
| 000149 (2021) |
Amir Sarayani [États-Unis] ; Brian Cicali [États-Unis] ; Carl H. Henriksen [États-Unis] ; Joshua D. Brown [États-Unis] | Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. |
| 000161 (2021) |
Eric Prommer [États-Unis] | Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. |
| 000165 (2021) |
Pablo Chicharro [Espagne] ; Pedro Rodríguez-Jiménez [Espagne] ; Ester Mu Oz-Aceituno [Espagne] ; Diego De Argila [Espagne] ; Patricia Mu Oz-Hernández [Espagne] ; Mar Llamas-Velasco [Espagne] | SDRIFE-like rash associated with COVID-19, clinicopathological correlation. |
| 000175 (2021) |
Okechukwu S. Ogah [Nigeria] ; Ejiroghene M. Umuerri ; Adewole Adebiyi [Nigeria] ; Olanike A. Orimolade [Nigeria] ; Mahmoud U. Sani ; Dike B. Ojji ; Amam C. Mbakwem ; Simon Stewart ; Karen Sliwa | SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications. |
| 000181 (2021) |
Pravindra Kumar [Inde] ; Ashok Kumar Sah [Inde] ; Greesham Tripathi [Inde] ; Anjali Kashyap [Inde] ; Avantika Tripathi [Inde] ; Rashmi Rao [Inde] ; Prabhu C. Mishra [Inde] ; Koustav Mallick [Inde] ; Amjad Husain [Inde] ; Manoj Kumar Kashyap [Inde] | Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. |
| 000196 (2021) |
A J J. Lammers [Pays-Bas] ; R M Brohet [Pays-Bas] ; R E P. Theunissen [Pays-Bas] ; C. Koster [Pays-Bas] ; R. Rood [Pays-Bas] ; D W M. Verhagen [Pays-Bas] ; K. Brinkman [Pays-Bas] ; R J Hassing [Pays-Bas] ; A. Dofferhoff [Pays-Bas] ; R. El Moussaoui [Pays-Bas] ; G. Hermanides [Pays-Bas] ; J. Ellerbroek [Pays-Bas] ; N. Bokhizzou [Pays-Bas] ; H. Visser [Pays-Bas] ; M. Van Den Berge [Pays-Bas] ; H. Bax [Pays-Bas] ; D F Postma [Pays-Bas] ; P H P. Groeneveld [Pays-Bas] | Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients". |
| 000199 (2021) |
Francesca Romana Spinelli [Italie] ; Fulvia Ceccarelli [Italie] ; Manuela Di Franco [Italie] ; Fabrizio Conti [Italie] | Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al. |
| 000200 (2021) |
Marijke Linschoten [Pays-Bas] ; Linda Nab [Pays-Bas] ; Iwan C C. Van Der Horst [Pays-Bas] ; Robert Tieleman [Pays-Bas] ; Folkert W. Asselbergs [Royaume-Uni] | Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients". |
| 000234 (2021) |
Carlos Diaz-Arocutipa [Pérou] ; Ana Bra Ez-Condorena [Pérou] ; Adrian V. Hernandez [Pérou, États-Unis] | QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. |
| 000249 (2021) |
Bianza Moise Bakadia ; Feng He [République populaire de Chine] ; Tiatou Souho [Togo] ; Lallepak Lamboni [Togo] ; Muhammad Wajid Ullah [République populaire de Chine] ; Biaou Ode Boni [République populaire de Chine] ; Abeer Ahmed Qaed Ahmed [République populaire de Chine] ; Biampata Mutu Mukole ; Guang Yang [République populaire de Chine] | Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. |
| 000289 (2021) |
Edgar Jg Peters [Pays-Bas] ; Didier Collard [Pays-Bas] ; Sander Van Assen [Pays-Bas] ; Martijn Beudel [Pays-Bas] ; Marije K. Bomers [Pays-Bas] ; Jacqueline Buijs [Pays-Bas] ; Lianne R. De Haan [Pays-Bas] ; Wouter De Ruijter [Pays-Bas] ; Renée A. Douma [Pays-Bas] ; Paul Wg Elbers [Pays-Bas] ; Abraham Goorhuis [Pays-Bas] ; Niels C. Gritters Van Den Oever [Pays-Bas] ; Lieve Ghh Knarren [Pays-Bas] ; Hazra S. Moeniralam [Pays-Bas] ; Remy Lm Mostard [Pays-Bas] ; Marian Jr Quanjel [Pays-Bas] ; Auke C. Reidinga [Pays-Bas] ; Roos Renckens [Pays-Bas] ; Joop Pw Van Den Bergh [Pays-Bas] ; Imro N. Vlasveld [Pays-Bas] ; Jonne J. Sikkens [Pays-Bas] | Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. |
| 000294 (2021) |
Sanjay Kumar Mishra [Inde] ; Timir Tripathi [Inde] | One year update on the COVID-19 pandemic: Where are we now? |
| 000295 (2021) |
Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine] | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. |
| 000322 (2021) |
Cathrine Axfors [États-Unis, Suède] ; Andreas M. Schmitt [Suisse] ; Perrine Janiaud [Suisse] ; Janneke Van'T Hooft [États-Unis, Pays-Bas] ; Sherief Abd-Elsalam [Égypte] ; Ehab F. Abdo [Égypte] ; Benjamin S. Abella [États-Unis] ; Javed Akram [Pakistan] ; Ravi K. Amaravadi [États-Unis] ; Derek C. Angus [États-Unis] ; Yaseen M. Arabi [Arabie saoudite] ; Shehnoor Azhar [Pakistan] ; Lindsey R. Baden [États-Unis] ; Arthur W. Baker [États-Unis] ; Leila Belkhir [Belgique] ; Thomas Benfield [Danemark] ; Marvin A H. Berrevoets [Pays-Bas] ; Cheng-Pin Chen [Taïwan] ; Tsung-Chia Chen [Taïwan] ; Shu-Hsing Cheng [Taïwan] ; Chien-Yu Cheng [Taïwan] ; Wei-Sheng Chung [Taïwan] ; Yehuda Z. Cohen [États-Unis] ; Lisa N. Cowan [États-Unis] ; Olav Dalgard [Norvège] ; Fernando F. De Almeida E Val [Brésil] ; Marcus V G. De Lacerda [Brésil] ; Gisely C. De Melo [Brésil] ; Lennie Derde [Pays-Bas] ; Vincent Dubee [France] ; Anissa Elfakir [France] ; Anthony C. Gordon [Royaume-Uni] ; Carmen M. Hernandez-Cardenas [Mexique] ; Thomas Hills [Nouvelle-Zélande] ; Andy I M. Hoepelman [Pays-Bas] ; Yi-Wen Huang [Taïwan] ; Bruno Igau [États-Unis] ; Ronghua Jin [République populaire de Chine] ; Felipe Jurado-Camacho [Mexique] ; Khalid S. Khan [Espagne] ; Peter G. Kremsner [Allemagne, Gabon] ; Benno Kreuels [Allemagne] ; Cheng-Yu Kuo [Taïwan] ; Thuy Le [États-Unis] ; Yi-Chun Lin [Taïwan] ; Wu-Pu Lin [Taïwan] ; Tse-Hung Lin [Taïwan] ; Magnus Nakrem Lyngbakken [Norvège] ; Colin Mcarthur [Nouvelle-Zélande, Australie] ; Bryan J. Mcverry [États-Unis] ; Patricia Meza-Meneses [Mexique] ; Wuelton M. Monteiro [Brésil] ; Susan C. Morpeth [Nouvelle-Zélande] ; Ahmad Mourad [États-Unis] ; Mark J. Mulligan [États-Unis] ; Srinivas Murthy [Canada] ; Susanna Naggie [États-Unis] ; Shanti Narayanasamy [États-Unis] ; Alistair Nichol [Australie, Irlande (pays)] ; Lewis A. Novack [États-Unis] ; Sean M. O'Brien [États-Unis] ; Nwora Lance Okeke [États-Unis] ; Léna Perez [France] ; Rogelio Perez-Padilla [Mexique] ; Laurent Perrin [France] ; Arantxa Remigio-Luna [Mexique] ; Norma E. Rivera-Martinez [Mexique] ; Frank W. Rockhold [États-Unis] ; Sebastian Rodriguez-Llamazares [Mexique] ; Robert Rolfe [États-Unis] ; Rossana Rosa [États-Unis] ; Helge R Sj [Norvège] ; Vanderson S. Sampaio [Brésil] ; Todd B. Seto [États-Unis] ; Muhammad Shahzad [Pakistan] ; Shaimaa Soliman [Égypte] ; Jason E. Stout [États-Unis] ; Ireri Thirion-Romero [Mexique] ; Andrea B. Troxel [États-Unis] ; Ting-Yu Tseng [Taïwan] ; Nicholas A. Turner [États-Unis] ; Robert J. Ulrich [États-Unis] ; Stephen R. Walsh [États-Unis] ; Steve A. Webb [Australie] ; Jesper M. Weehuizen [Pays-Bas] ; Maria Velinova [Pays-Bas] ; Hon-Lai Wong [Taïwan] ; Rebekah Wrenn [États-Unis] ; Fernando G. Zampieri [Brésil] ; Wu Zhong [République populaire de Chine] ; David Moher [Canada] ; Steven N. Goodman [États-Unis] ; John P A. Ioannidis [États-Unis, Allemagne] ; Lars G. Hemkens [États-Unis, Suisse, Allemagne] | Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. |
| 000324 (2021) |
S. Verheijen [Pays-Bas] ; M. Van Luin [Pays-Bas] ; R J Brüggemann [Pays-Bas] ; Q. De Mast [Pays-Bas] ; R J Hassing [Pays-Bas] ; D M Burger [Pays-Bas] | More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine. |
| 000342 (2021) |
T S Brandon Ng ; Kori Leblanc ; Darwin F. Yeung ; Teresa S M. Tsang [Canada] | Medication use during COVID-19: Review of recent evidence. |
| 000360 (2021) |
Sergey Moiseev [Oman] ; Sergey Avdeev [Russie] ; Michail Brovko [Russie] ; Pavel Novikov [Russie] ; Victor Fomin [Russie] | Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? |
| 000361 (2021) |
| Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus? |
| 000362 (2021) |
| Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus? |
| 000373 (2021) |
Irina Panovska-Stavridis ; Nevenka Ridova ; Tatjana Stojanoska ; Ilir Demiri ; Milena Stevanovic ; Simona Stojanovska ; Tara Ristevska ; Aleksandar Dimkovski ; Venko Filipce ; Aleksandar Dimovski ; Aleksandra Grozdanova | Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). |
| 000381 (2021) |
Rosa Maria Vivanco-Hidalgo [Espagne] ; Israel Molina [Espagne] ; Elisenda Martinez [Espagne] ; Ram N Roman-Vi As [Espagne] ; Adrián Sánchez-Montalvá [Espagne] ; Joan Fibla [Espagne] ; Caridad Pontes [Espagne] ; César Velasco Mu Oz [Espagne] | Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. |
| 000391 (2021) |
Yufeng Shang [République populaire de Chine] ; Tao Liu [République populaire de Chine] ; Jingfeng Li [République populaire de Chine] ; Natasha Mupeta Kaweme [République populaire de Chine] ; Xinghuan Wang [République populaire de Chine] ; Fuling Zhou [République populaire de Chine] | Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus. |
| 000400 (2021) |
Yao Chen ; Mei-Xiu Li ; Guo-Dong Lu ; Han-Ming Shen [République populaire de Chine, Singapour] ; Jing Zhou [Singapour] | Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. |
| 000427 (2021) |
Marco Infante [Italie, États-Unis] ; Camillo Ricordi [États-Unis] ; Rodolfo Alejandro [États-Unis] ; Massimiliano Caprio [Italie] ; Andrea Fabbri [Italie] | Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. |
| 000446 (2021) |
Massimo Nicol [Italie] ; Lorenzo Ferro Desideri [Italie] ; Matteo Bassetti [Italie] ; Carlo Enrico Traverso [Italie] | Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. |
| 000449 (2021) |
Nathan Peiffer-Smadja [France] ; Mathieu E. Rebeaud [Suisse] ; Anthony Guihur [Suisse] ; Yahya Mahamat-Saleh [France] ; Thibault Fiolet [France] | Hydroxychloroquine and COVID-19: a tale of populism and obscurantism. |
| 000487 (2021) |
M. Ortega-Pe A [Chili] ; R. González-Cuevas [Chili] | Familiar Dermatologic Drugs as Therapies for COVID-19. |
| 000491 (2021) |
Gaurav Joshi [Inde] ; Shikha Thakur [Inde] ; Mayank [Inde] ; Ramarao Poduri [Inde] | Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. |
| 000503 (2021) |
Qiuyu Li [République populaire de Chine] ; Cheng Cui [République populaire de Chine] ; Fei Xu [République populaire de Chine] ; Jianping Zhao [République populaire de Chine] ; Nan Li [République populaire de Chine] ; Haichao Li [République populaire de Chine] ; Tianbing Wang [République populaire de Chine] ; Hua Zhang [République populaire de Chine] ; Na Liu [République populaire de Chine] ; Yudong Wei [République populaire de Chine] ; Xiaoye Niu [République populaire de Chine] ; Yan Xu [République populaire de Chine] ; Jianping Dong [République populaire de Chine] ; Xueting Yao [République populaire de Chine] ; Xiaohong Wang [République populaire de Chine] ; Yahong Chen [République populaire de Chine] ; Haiyan Li [République populaire de Chine] ; Chunli Song [République populaire de Chine] ; Jie Qiao [République populaire de Chine] ; Dongyang Liu [République populaire de Chine] ; Ning Shen [République populaire de Chine] | Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19. |
| 000511 (2021) |
Rujipas Sirijatuphat [Thaïlande] ; Yupin Suputtamongkol [Thaïlande] ; Nasikarn Angkasekwinai [Thaïlande] ; Navin Horthongkham [Thaïlande] ; Methee Chayakulkeeree [Thaïlande] ; Pinyo Rattanaumpawan [Thaïlande] ; Pornpan Koomanachai [Thaïlande] ; Susan Assanasen [Thaïlande] ; Yong Rongrungruang [Thaïlande] ; Nitipatana Chierakul [Thaïlande] ; Ranistha Ratanarat [Thaïlande] ; Anupop Jitmuang [Thaïlande] ; Walaiporn Wangchinda [Thaïlande] ; Wannee Kantakamalakul [Thaïlande] | Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. |
| 000514 (2021) |
Maria Gavriatopoulou [Grèce] ; Ioannis Ntanasis-Stathopoulos [Grèce] ; Eleni Korompoki [Grèce, Royaume-Uni] ; Despina Fotiou [Grèce] ; Magdalini Migkou [Grèce] ; Ioannis-Georgios Tzanninis [Royaume-Uni] ; Theodora Psaltopoulou [Grèce] ; Efstathios Kastritis [Grèce] ; Evangelos Terpos [Grèce] ; Meletios A. Dimopoulos [Grèce] | Emerging treatment strategies for COVID-19 infection. |
| 000519 (2021) |
Zakariya Kashour [Canada] ; Muhammad Riaz [Pakistan] ; Musa A. Garbati [Nigeria] ; Oweida Aldosary [Arabie saoudite] ; Haytham Tlayjeh [Arabie saoudite] ; Dana Gerberi [États-Unis] ; M Hassan Murad [États-Unis] ; M Rizwan Sohail [États-Unis] ; Tarek Kashour [Arabie saoudite] ; Imad M. Tleyjeh [Arabie saoudite, États-Unis] | Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. |
| 000521 (2021) |
Daniela R. Junqueira [Canada] ; Brian H. Rowe [Canada] | Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. |
| 000522 (2021) |
Jogender Kumar [Inde] ; Siddharth Jain [Inde] ; Jitendra Meena [Inde] ; Arushi Yadav [Inde] | Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. |
| 000536 (2021) |
Thibault Fiolet [France] ; Anthony Guihur [Suisse] ; Mathieu Edouard Rebeaud [Suisse] ; Matthieu Mulot [Suisse] ; Nathan Peiffer-Smadja [France] ; Yahya Mahamat-Saleh [France] | Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. |
| 000537 (2021) |
Thibault Fiolet [France] ; Anthony Guihur [Suisse] ; Mathieu Edouard Rebeaud [Suisse] ; Matthieu Mulot [Suisse] ; Nathan Peiffer-Smadja [France] ; Yahya Mahamat-Saleh [France] | Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. |
| 000557 (2021) |
Nitesh Sanghai [Canada] ; Kashfia Shafiq [Canada] ; Geoffrey K. Tranmer [Canada] | Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. |
| 000568 (2021) |
Vong Sok [États-Unis] ; Florence Marzan [États-Unis] ; David Gingrich [États-Unis] ; Francesca Aweeka [États-Unis] ; Liusheng Huang [États-Unis] | Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. |
| 000571 (2021) |
Mukesh Kumar [Inde] ; Jitender Madan [Inde] ; Rupinder Kaur Sodhi [Inde] ; Shashi Bala Singh [Inde] ; Anju Katyal [Inde] | Decoding the silent walk of COVID-19: Halting its spread using old bullets. |
| 000587 (2021) |
Susan Gould [Royaume-Uni] ; Susan L. Norris [États-Unis] | Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19. |
